[Toxicity of pyrazinamide in antituberculous treatments (author's transl)].
Pyrazinamide, an antituberculous drug discovered in 1952, was first considered as a toxic drug. As it appeared as a bactericidal drug for the organisms inside macrophages, its usefulness has been re-appraised. In combination with other bactericidal drugs, it contributes to speed up the sterilization of tuberculous lesions. A review of the more recent clinical trials allows to assess the real toxicity of Pyrazinamide. Prescribed at a daily dosage of 30 to 35 mg/kg (1,5 to 2 g daily), it gives no major side effects.
D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003967:Diarrhea / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D006073:Gout / Q000139:chemically induced; D006801:Humans; D007538:Isoniazid / Q000633:toxicity; D009325:Nausea / Q000139:chemically induced; D011718:Pyrazinamide / Q000627:therapeutic use / Q000633:toxicity*; D012293:Rifampin / Q000633:toxicity; D013307:Streptomycin / Q000633:toxicity; D014376:Tuberculosis / Q000188:drug therapy*
D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
La toxicité du pyrazinamide dans les traitements antituberculeux.